Brief: Boundless Bio Announces First Patient Dosed In First-in-Human Phase 1/2 Clinical Trial Of BBI-825 In Cancer Patients With Resistance Gene Amplifications11/04/2024 15:17
Brief: Boundless Bio Filed Amended And Restated Certificate Of Incorporation With Secretary Of State Of Delaware In Connection With Closing Of IPO02/04/2024 21:14
Brief: Boundless Bio Announces Pricing Of Its Initial Public Offering Of 6.25 Mln Shares At $16.00 Per Share28/03/2024 24:57
Last trade - 00:00Last trade - 00:00Last trade - 00:00